Noveris Health Sciences Inc. MYCOF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 168.20% | -12.10% | -99.23% | -114.22% | -68.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 184.58% | -12.10% | 100.25% | -106.71% | -89.46% |
| Operating Income | -184.58% | 12.10% | -100.25% | 106.71% | 89.46% |
| Income Before Tax | 271.28% | -458.31% | 26.85% | 103.67% | 99.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 271.28% | -458.31% | 26.85% | 103.67% | 99.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 271.28% | -458.31% | 26.85% | 103.67% | 99.52% |
| EBIT | -184.58% | 12.10% | -100.25% | 106.71% | 89.46% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 103.95% | 56.58% | 26.59% | 103.67% | 99.52% |
| Normalized Basic EPS | 97.54% | 73.75% | -126.78% | 103.67% | 95.11% |
| EPS Diluted | 103.95% | 56.58% | 26.59% | 103.67% | 99.52% |
| Normalized Diluted EPS | 97.54% | 73.75% | -126.78% | 103.67% | 95.11% |
| Average Basic Shares Outstanding | 4,640.35% | 1,185.08% | 0.20% | 0.00% | 0.92% |
| Average Diluted Shares Outstanding | 4,640.35% | 1,185.08% | 0.20% | 0.00% | 0.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |